data_1ylb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ylb _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' B' B ' 100' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 1' ' ' VAL . . . . . . . . . . . . . 56.8 t . . . . . 0 N--CA 1.478 0.965 0 N-CA-C 109.487 -0.56 . . . . 0.02 109.487 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 2' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.57 95.89 6.53 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-O 121.427 0.632 . . . . 0.02 110.564 172.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -70.21 114.5 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 O-C-N 120.918 -1.114 . . . . 0.02 110.457 -177.544 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 4' ' ' LEU . . . . . . . . . . . . . 18.8 tp -85.43 100.5 11.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.404 1.081 . . . . 0.02 112.084 -169.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -71.85 103.75 3.25 Favored 'General case' 0 CA--C 1.536 0.413 0 O-C-N 121.338 -0.851 . . . . 0.02 112.151 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 6' ' ' GLY . . . . . . . . . . . . . . . 124.84 44.22 0.28 Allowed Glycine 0 CA--C 1.523 0.543 0 CA-C-O 119.136 -0.813 . . . . 0.01 112.741 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -26.5 90.44 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 127.243 2.354 . . . . 0.01 116.144 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.73 16.11 44.24 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.112 -1.382 . . . . 0.0 115.034 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' ASP . . . . . . . . . . . . . 34.8 t0 69.17 -39.91 0.44 Allowed 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 120.22 2.01 . . . . 0.06 113.703 -174.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.21 4.6 85.31 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 125.18 1.372 . . . . 0.03 113.793 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 50.7 m -136.02 108.44 7.37 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 119.291 1.546 . . . . 0.01 110.014 163.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' LEU . . . . . . . . . . . . . 23.3 tp -70.45 74.61 0.54 Allowed 'General case' 0 CA--C 1.533 0.325 0 O-C-N 121.452 -0.78 . . . . 0.03 111.524 -177.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.57 173.02 16.9 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 122.981 0.512 . . . . 0.02 110.536 -165.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.78 164.92 20.3 Favored 'General case' 0 C--N 1.33 -0.246 0 O-C-N 121.935 -0.478 . . . . 0.02 111.426 166.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' LEU . . . . . . . . . . . . . 34.8 mt -133.91 118.66 14.39 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 123.487 0.715 . . . . 0.02 109.513 152.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -72.41 161.34 92.86 Favored 'Cis proline' 0 CA--C 1.533 0.443 0 CA-C-N 119.919 1.007 . . . . 0.02 112.972 -3.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -100.22 -12.46 39.15 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 123.87 0.747 . . . . 0.03 112.244 172.734 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -142.67 126.06 16.65 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.558 1.143 . . . . 0.03 109.769 168.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -151.86 175.02 12.89 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.0 -1.063 . . . . 0.02 109.976 174.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 8.1 m -131.32 157.84 42.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 118.369 0.531 . . . . 0.02 109.897 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 17.1 m -142.03 169.78 13.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 110.155 -0.313 . . . . 0.02 110.155 -177.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -99.22 162.32 13.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.759 0.79 . . . . 0.02 111.186 167.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 4.9 t -70.88 132.67 45.6 Favored 'General case' 0 C--N 1.327 -0.392 0 O-C-N 120.874 -1.141 . . . . 0.02 110.448 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.79 -0.21 69.76 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.431 1.015 . . . . 0.02 113.079 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -83.02 170.31 15.01 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.787 -0.831 . . . . 0.02 110.449 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -118.5 127.25 53.46 Favored 'General case' 0 C--O 1.233 0.185 0 O-C-N 121.715 -0.616 . . . . 0.02 111.616 -175.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.08 134.23 31.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 108.637 -0.875 . . . . 0.02 108.637 169.508 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -110.31 113.45 44.25 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.082 -0.71 . . . . 0.02 109.082 174.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -94.29 120.49 34.6 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 120.983 -1.073 . . . . 0.02 109.414 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 41.3 pttt -130.51 153.67 48.59 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 121.343 -0.848 . . . . 0.03 111.955 -177.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -75.89 161.4 29.0 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.079 0.552 . . . . 0.03 111.242 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -138.34 -43.25 0.5 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 120.849 -1.157 . . . . 0.02 113.501 165.057 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.36 172.51 18.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 118.275 -0.869 . . . . 0.03 109.14 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . 67.61 29.56 74.06 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 119.586 1.084 . . . . 0.09 115.27 165.216 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -59.87 160.98 13.14 Favored Pre-proline 0 C--O 1.236 0.381 0 N-CA-C 114.119 1.155 . . . . 0.09 114.119 -167.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.18 171.02 34.0 Favored 'Cis proline' 0 CA--C 1.53 0.322 0 C-N-CA 129.175 0.906 . . . . 0.06 113.083 -3.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -144.01 177.59 8.46 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.025 0.53 . . . . 0.05 112.203 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' ASN . . . . . . . . . . . . . 41.5 p-10 -159.85 -178.57 7.14 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.181 1.392 . . . . 0.1 107.356 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.5 133.18 65.7 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-O 121.73 0.776 . . . . 0.07 111.439 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 47.6 t -132.4 120.0 41.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 114.421 -1.263 . . . . 0.11 110.176 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 41' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -77.72 135.4 38.03 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.319 -0.863 . . . . 0.12 110.529 173.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -79.29 107.84 12.35 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.215 -0.928 . . . . 0.34 113.018 -170.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 43' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -58.47 -10.68 2.29 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 115.573 1.694 . . . . 0.33 115.573 -167.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -100.39 -10.75 20.87 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.937 0.895 . . . . 0.34 112.841 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 45' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -128.5 -13.17 4.89 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 114.321 1.23 . . . . 0.55 114.321 -173.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 46' ' ' ILE . . . . . . . . . . . . . 10.7 pt -56.05 163.45 2.26 Favored Pre-proline 0 N--CA 1.475 0.788 0 CA-C-N 118.926 0.784 . . . . 0.07 111.606 167.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 47' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -71.04 165.18 33.22 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 121.066 1.178 . . . . 0.05 110.963 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 48' ' ' SER . . . . . . . . . . . . . 28.3 m -75.14 -28.6 60.23 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 121.35 -0.844 . . . . 0.04 112.724 -171.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -78.73 18.09 6.22 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 116.092 1.197 . . . . 0.04 116.092 -173.598 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 50' ' ' VAL . . . . . . . . . . . . . 2.8 p -145.8 169.17 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 119.012 1.406 . . . . 0.05 109.99 -178.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -118.43 128.61 54.78 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.045 1.338 . . . . 0.1 108.838 166.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 52' ' ' ALA . . . . . . . . . . . . . . . -53.66 -26.97 24.83 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.433 -0.792 . . . . 0.09 111.66 177.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.76 -8.23 10.0 Favored 'General case' 0 CA--C 1.541 0.603 0 O-C-N 120.551 -1.343 . . . . 0.07 114.404 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 54' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -98.67 -7.41 27.92 Favored 'General case' 0 N--CA 1.468 0.43 0 O-C-N 121.251 -0.905 . . . . 0.06 113.076 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 55' ' ' ILE . . . . . . . . . . . . . 40.3 pt -130.95 -25.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 113.698 0.999 . . . . 0.06 113.698 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -71.58 160.69 32.23 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 120.866 -1.146 . . . . 0.1 111.334 165.055 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 57' ' ' MET . . . . . . . . . . . . . 85.8 mtp -73.54 168.12 19.92 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.658 -0.651 . . . . 0.08 110.649 166.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 1.5 m -70.71 155.25 41.0 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.659 -0.65 . . . . 0.1 111.503 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 59' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -61.14 -27.97 68.77 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 114.498 1.295 . . . . 0.28 114.498 -167.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -111.53 15.48 21.15 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 124.206 1.002 . . . . 0.24 112.4 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -101.84 113.91 27.52 Favored 'General case' 0 CA--C 1.536 0.405 0 O-C-N 121.48 -0.762 . . . . 0.06 111.5 172.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 62' ' ' LEU . . . . . . . . . . . . . 4.0 mp -137.83 150.15 46.94 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.328 -0.857 . . . . 0.05 111.39 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 63' ' ' LEU . . . . . . . . . . . . . 44.4 mt -82.72 110.32 17.66 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 127.207 2.203 . . . . 0.03 109.942 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -112.95 -16.29 12.71 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 114.861 1.43 . . . . 0.02 114.861 -166.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.57 165.97 12.0 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 118.595 0.634 . . . . 0.01 110.659 171.831 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -48.71 -54.17 5.79 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.901 3.067 . . . . 0.01 114.652 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -88.59 2.63 84.81 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.92 -1.112 . . . . 0.01 114.893 -166.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -70.19 155.76 40.18 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 119.178 1.489 . . . . 0.02 112.961 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -140.48 164.0 31.3 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 122.235 1.017 . . . . 0.02 113.42 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -137.09 151.54 49.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 106.916 -1.512 . . . . 0.03 106.916 167.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' LYS . . . . . . . . . . . . . 43.4 mtmt -141.33 149.08 40.72 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.704 1.138 . . . . 0.03 111.446 -173.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.12 128.83 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 112.512 0.56 . . . . 0.02 112.512 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' THR . . . . . . . . . . . . . 61.8 m -76.79 128.02 33.83 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.131 -1.063 . . . . 0.02 108.131 162.516 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' LEU . . . . . . . . . . . . . 5.8 tp -118.2 154.67 31.82 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.153 0.888 . . . . 0.02 111.594 -173.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' THR . . . . . . . . . . . . . 39.1 p -152.49 176.91 11.18 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.169 -1.048 . . . . 0.03 108.169 -176.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 78.28 115.53 0.06 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 128.082 2.553 . . . . 0.03 111.901 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -70.12 101.25 1.8 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 123.779 0.831 . . . . 0.03 112.313 -175.03 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.15 177.38 44.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.881 -0.488 . . . . 0.03 111.881 173.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.75 143.75 55.73 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 124.145 0.978 . . . . 0.05 112.556 173.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' TYR . . . . . 0.451 ' CB ' HG11 ' B' ' 96' ' ' VAL 0.338 26.5 m-85 -135.04 82.05 1.93 Allowed 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 124.498 2.094 . . . . 0.05 111.332 -175.79 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -71.01 115.4 10.09 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 119.725 -1.86 . . . . 0.09 110.804 162.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -126.43 139.45 53.24 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 122.748 1.261 . . . . 0.07 108.078 163.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -133.23 177.12 7.92 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.286 -1.325 . . . . 0.25 107.601 -173.698 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 t -110.68 108.96 19.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.555 -0.535 . . . . 0.09 109.555 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' SER . . . . . . . . . . . . . 1.8 p -56.16 -32.07 11.86 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 116.478 2.029 . . . . 0.12 116.478 -162.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -63.43 -28.21 71.02 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 CA-C-N 122.113 1.79 . . . . 0.15 113.669 171.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -122.84 -4.27 8.62 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 114.221 1.193 . . . . 0.06 114.221 -166.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -57.14 -37.82 72.59 Favored 'General case' 0 N--CA 1.467 0.419 0 O-C-N 121.092 -1.005 . . . . 0.37 112.079 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -75.29 -32.38 55.69 Favored Glycine 0 CA--C 1.528 0.877 0 O-C-N 120.487 -1.383 . . . . 0.03 111.31 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' ALA . . . . . . . . . . . . . . . -70.19 -9.24 55.12 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.621 -0.929 . . . . 0.05 112.322 172.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' GLY . . . . . . . . . . . . . . . 121.91 -9.35 9.76 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.726 0.679 . . . . 0.04 113.767 170.56 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' MET . . . . . . . . . . . . . 16.6 ttt -72.07 86.38 1.04 Allowed 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.439 1.12 . . . . 0.05 112.797 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' VAL . . . . . . . . . . . . . 4.2 t -128.72 142.17 44.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 124.244 1.018 . . . . 0.05 108.865 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -126.23 151.75 18.03 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 109.497 -1.441 . . . . 0.04 109.497 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' LYS . . . . . . . . . . . . . 13.0 ttpp -123.92 93.32 3.89 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 123.38 0.672 . . . . 0.04 110.456 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' VAL . . . . . 0.451 HG11 ' CB ' ' B' ' 80' ' ' TYR . 8.2 p -78.2 162.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 107.21 -1.404 . . . . 0.03 107.21 164.65 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' THR . . . . . . . . . . . . . 18.3 m -153.93 130.89 10.96 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 119.742 -1.849 . . . . 0.03 107.435 173.696 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' VAL . . . . . . . . . . . . . 58.9 t -89.65 111.69 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 108.732 -0.84 . . . . 0.02 108.732 178.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.247 0.933 0 N-CA-C 114.024 1.12 . . . . 0.02 114.024 -170.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 100' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 1' ' ' VAL . . . . . . . . . . . . . 56.8 t . . . . . 0 N--CA 1.478 0.965 0 N-CA-C 109.487 -0.56 . . . . 0.02 109.487 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 2' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.57 95.89 6.53 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-O 121.427 0.632 . . . . 0.02 110.564 172.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -70.21 114.5 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 O-C-N 120.918 -1.114 . . . . 0.02 110.457 -177.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 4' ' ' LEU . . . . . . . . . . . . . 18.8 tp -85.43 100.5 11.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.404 1.081 . . . . 0.02 112.084 -169.894 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -71.85 103.75 3.25 Favored 'General case' 0 CA--C 1.536 0.413 0 O-C-N 121.338 -0.851 . . . . 0.02 112.151 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 6' ' ' GLY . . . . . . . . . . . . . . . 124.84 44.22 0.28 Allowed Glycine 0 CA--C 1.523 0.543 0 CA-C-O 119.136 -0.813 . . . . 0.01 112.741 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -26.5 90.44 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 127.243 2.354 . . . . 0.01 116.144 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.73 16.11 44.24 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.112 -1.382 . . . . 0.0 115.034 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 9' ' ' ASP . . . . . . . . . . . . . 34.8 t0 69.17 -39.91 0.44 Allowed 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 120.22 2.01 . . . . 0.06 113.703 -174.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.21 4.6 85.31 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 125.18 1.372 . . . . 0.03 113.793 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 50.7 m -136.02 108.44 7.37 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 119.291 1.546 . . . . 0.01 110.014 163.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 12' ' ' LEU . . . . . . . . . . . . . 23.3 tp -70.45 74.61 0.54 Allowed 'General case' 0 CA--C 1.533 0.325 0 O-C-N 121.452 -0.78 . . . . 0.03 111.524 -177.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.57 173.02 16.9 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 122.981 0.512 . . . . 0.02 110.536 -165.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 14' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.78 164.92 20.3 Favored 'General case' 0 C--N 1.33 -0.246 0 O-C-N 121.935 -0.478 . . . . 0.02 111.426 166.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' LEU . . . . . . . . . . . . . 34.8 mt -133.91 118.66 14.39 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 123.487 0.715 . . . . 0.02 109.513 152.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -72.41 161.34 92.86 Favored 'Cis proline' 0 CA--C 1.533 0.443 0 CA-C-N 119.919 1.007 . . . . 0.02 112.972 -3.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -100.22 -12.46 39.15 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 123.87 0.747 . . . . 0.03 112.244 172.734 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -142.67 126.06 16.65 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.558 1.143 . . . . 0.03 109.769 168.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -151.86 175.02 12.89 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.0 -1.063 . . . . 0.02 109.976 174.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 8.1 m -131.32 157.84 42.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 118.369 0.531 . . . . 0.02 109.897 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 17.1 m -142.03 169.78 13.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 110.155 -0.313 . . . . 0.02 110.155 -177.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -99.22 162.32 13.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.759 0.79 . . . . 0.02 111.186 167.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 4.9 t -70.88 132.67 45.6 Favored 'General case' 0 C--N 1.327 -0.392 0 O-C-N 120.874 -1.141 . . . . 0.02 110.448 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.79 -0.21 69.76 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.431 1.015 . . . . 0.02 113.079 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -83.02 170.31 15.01 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.787 -0.831 . . . . 0.02 110.449 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -118.5 127.25 53.46 Favored 'General case' 0 C--O 1.233 0.185 0 O-C-N 121.715 -0.616 . . . . 0.02 111.616 -175.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.08 134.23 31.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 108.637 -0.875 . . . . 0.02 108.637 169.508 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -110.31 113.45 44.25 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.082 -0.71 . . . . 0.02 109.082 174.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -94.29 120.49 34.6 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 120.983 -1.073 . . . . 0.02 109.414 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 41.3 pttt -130.51 153.67 48.59 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 121.343 -0.848 . . . . 0.03 111.955 -177.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -75.89 161.4 29.0 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.079 0.552 . . . . 0.03 111.242 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -138.34 -43.25 0.5 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 120.849 -1.157 . . . . 0.02 113.501 165.057 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.36 172.51 18.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 118.275 -0.869 . . . . 0.03 109.14 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . 67.61 29.56 74.06 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 119.586 1.084 . . . . 0.09 115.27 165.216 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 35' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -59.87 160.98 13.14 Favored Pre-proline 0 C--O 1.236 0.381 0 N-CA-C 114.119 1.155 . . . . 0.09 114.119 -167.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 36' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.18 171.02 34.0 Favored 'Cis proline' 0 CA--C 1.53 0.322 0 C-N-CA 129.175 0.906 . . . . 0.06 113.083 -3.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -144.01 177.59 8.46 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.025 0.53 . . . . 0.05 112.203 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' ASN . . . . . . . . . . . . . 41.5 p-10 -159.85 -178.57 7.14 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.181 1.392 . . . . 0.1 107.356 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.5 133.18 65.7 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-O 121.73 0.776 . . . . 0.07 111.439 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 47.6 t -132.4 120.0 41.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 114.421 -1.263 . . . . 0.11 110.176 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 41' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -77.72 135.4 38.03 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.319 -0.863 . . . . 0.12 110.529 173.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -79.29 107.84 12.35 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.215 -0.928 . . . . 0.34 113.018 -170.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 43' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -58.47 -10.68 2.29 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 115.573 1.694 . . . . 0.33 115.573 -167.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -100.39 -10.75 20.87 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.937 0.895 . . . . 0.34 112.841 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 45' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -128.5 -13.17 4.89 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 114.321 1.23 . . . . 0.55 114.321 -173.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 46' ' ' ILE . . . . . . . . . . . . . 10.7 pt -56.05 163.45 2.26 Favored Pre-proline 0 N--CA 1.475 0.788 0 CA-C-N 118.926 0.784 . . . . 0.07 111.606 167.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 47' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -71.04 165.18 33.22 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 121.066 1.178 . . . . 0.05 110.963 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 48' ' ' SER . . . . . . . . . . . . . 28.3 m -75.14 -28.6 60.23 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 121.35 -0.844 . . . . 0.04 112.724 -171.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -78.73 18.09 6.22 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 116.092 1.197 . . . . 0.04 116.092 -173.598 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 50' ' ' VAL . . . . . . . . . . . . . 2.8 p -145.8 169.17 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 119.012 1.406 . . . . 0.05 109.99 -178.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -118.43 128.61 54.78 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.045 1.338 . . . . 0.1 108.838 166.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 52' ' ' ALA . . . . . . . . . . . . . . . -53.66 -26.97 24.83 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.433 -0.792 . . . . 0.09 111.66 177.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.76 -8.23 10.0 Favored 'General case' 0 CA--C 1.541 0.603 0 O-C-N 120.551 -1.343 . . . . 0.07 114.404 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 54' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -98.67 -7.41 27.92 Favored 'General case' 0 N--CA 1.468 0.43 0 O-C-N 121.251 -0.905 . . . . 0.06 113.076 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 55' ' ' ILE . . . . . . . . . . . . . 40.3 pt -130.95 -25.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 113.698 0.999 . . . . 0.06 113.698 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -71.58 160.69 32.23 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 120.866 -1.146 . . . . 0.07 111.334 165.055 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 57' ' ' MET . . . . . . . . . . . . . 85.8 mtp -73.54 168.12 19.92 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.658 -0.651 . . . . 0.08 110.649 166.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 1.5 m -70.71 155.25 41.0 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.659 -0.65 . . . . 0.1 111.503 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 59' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -61.14 -27.97 68.77 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 114.498 1.295 . . . . 0.28 114.498 -167.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -111.53 15.48 21.15 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 124.206 1.002 . . . . 0.24 112.4 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -101.84 113.91 27.52 Favored 'General case' 0 CA--C 1.536 0.405 0 O-C-N 121.48 -0.762 . . . . 0.06 111.5 172.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 62' ' ' LEU . . . . . . . . . . . . . 4.0 mp -137.83 150.15 46.94 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.328 -0.857 . . . . 0.05 111.39 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 63' ' ' LEU . . . . . . . . . . . . . 44.4 mt -82.72 110.32 17.66 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 127.207 2.203 . . . . 0.03 109.942 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -112.95 -16.29 12.71 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 114.861 1.43 . . . . 0.02 114.861 -166.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.57 165.97 12.0 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 118.595 0.634 . . . . 0.01 110.659 171.831 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -48.71 -54.17 5.79 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.901 3.067 . . . . 0.01 114.652 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -88.59 2.63 84.81 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.92 -1.112 . . . . 0.01 114.893 -166.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -70.19 155.76 40.18 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 119.178 1.489 . . . . 0.02 112.961 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -140.48 164.0 31.3 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 122.235 1.017 . . . . 0.02 113.42 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -137.09 151.54 49.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 106.916 -1.512 . . . . 0.03 106.916 167.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 71' ' ' LYS . . . . . . . . . . . . . 43.4 mtmt -141.33 149.08 40.72 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.704 1.138 . . . . 0.03 111.446 -173.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.12 128.83 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 112.512 0.56 . . . . 0.02 112.512 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 73' ' ' THR . . . . . . . . . . . . . 61.8 m -76.79 128.02 33.83 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.131 -1.063 . . . . 0.02 108.131 162.516 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' LEU . . . . . . . . . . . . . 5.8 tp -118.2 154.67 31.82 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.153 0.888 . . . . 0.02 111.594 -173.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' THR . . . . . . . . . . . . . 39.1 p -152.49 176.91 11.18 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.169 -1.048 . . . . 0.03 108.169 -176.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 76' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 78.28 115.53 0.06 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 128.082 2.553 . . . . 0.03 111.901 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -70.12 101.25 1.8 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 123.779 0.831 . . . . 0.03 112.313 -175.03 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.15 177.38 44.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.881 -0.488 . . . . 0.03 111.881 173.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.75 143.75 55.73 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 124.145 0.978 . . . . 0.05 112.556 173.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' TYR . . . . . 0.65 ' CB ' HG13 ' B' ' 96' ' ' VAL 0.338 26.5 m-85 -135.04 82.05 1.93 Allowed 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 124.498 2.094 . . . . 0.05 111.332 -175.79 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 81' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -71.01 115.4 10.09 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 119.725 -1.86 . . . . 0.09 110.804 162.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' PHE . . . . . 0.487 ' HE1' ' H ' ' B' ' 96' ' ' VAL . 0.4 OUTLIER -126.43 139.45 53.24 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 122.748 1.261 . . . . 0.07 108.078 163.343 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 83' ' ' TYR . . . . . 0.411 ' HB3' HG13 ' B' ' 93' ' ' VAL . 0.1 OUTLIER -133.23 177.12 7.92 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.286 -1.325 . . . . 0.15 107.601 -173.698 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 t -110.68 108.96 19.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.555 -0.535 . . . . 0.09 109.555 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 85' ' ' SER . . . . . . . . . . . . . 1.8 p -56.16 -32.07 11.86 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 116.478 2.029 . . . . 0.09 116.478 -162.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -63.43 -28.21 71.02 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 CA-C-N 122.113 1.79 . . . . 0.15 113.669 171.398 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -122.84 -4.27 8.62 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 114.221 1.193 . . . . 0.05 114.221 -166.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 88' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -57.14 -37.82 72.59 Favored 'General case' 0 N--CA 1.467 0.419 0 O-C-N 121.092 -1.005 . . . . 0.27 112.079 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -75.29 -32.38 55.69 Favored Glycine 0 CA--C 1.528 0.877 0 O-C-N 120.487 -1.383 . . . . 0.0 111.31 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 90' ' ' ALA . . . . . . . . . . . . . . . -70.19 -9.24 55.12 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.621 -0.929 . . . . 0.05 112.322 172.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' GLY . . . . . . . . . . . . . . . 121.91 -9.35 9.76 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.726 0.679 . . . . 0.04 113.767 170.56 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' MET . . . . . . . . . . . . . 16.6 ttt -72.07 86.38 1.04 Allowed 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.439 1.12 . . . . 0.05 112.797 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' VAL . . . . . 0.411 HG13 ' HB3' ' B' ' 83' ' ' TYR . 4.2 t -128.72 142.17 44.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 124.244 1.018 . . . . 0.05 108.865 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -126.23 151.75 18.03 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 109.497 -1.441 . . . . 0.04 109.497 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' LYS . . . . . . . . . . . . . 13.0 ttpp -123.92 93.32 3.89 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 123.38 0.672 . . . . 0.04 110.456 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' VAL . . . . . 0.65 HG13 ' CB ' ' B' ' 80' ' ' TYR . 8.2 p -78.2 162.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 107.21 -1.404 . . . . 0.03 107.21 164.65 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' THR . . . . . . . . . . . . . 18.3 m -153.93 130.89 10.96 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 119.742 -1.849 . . . . 0.03 107.435 173.696 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' VAL . . . . . . . . . . . . . 58.9 t -89.65 111.69 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 108.732 -0.84 . . . . 0.02 108.732 178.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.247 0.933 0 N-CA-C 114.024 1.12 . . . . 0.02 114.024 -170.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 100' ' ' CU1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 1' ' ' VAL . . . . . . . . . . . . . 56.8 t . . . . . 0 N--CA 1.478 0.965 0 N-CA-C 109.487 -0.56 . . . . 0.02 109.487 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 2' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.57 95.89 6.53 Favored 'General case' 0 CA--C 1.536 0.43 0 CA-C-O 121.427 0.632 . . . . 0.02 110.564 172.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 3' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -70.21 114.5 7.89 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 O-C-N 120.918 -1.114 . . . . 0.02 110.457 -177.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 4' ' ' LEU . . . . . . . . . . . . . 18.8 tp -85.43 100.5 11.91 Favored 'General case' 0 N--CA 1.452 -0.345 0 C-N-CA 124.404 1.081 . . . . 0.02 112.084 -169.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 5' ' ' LEU . . . . . . . . . . . . . 2.8 mp -71.85 103.75 3.25 Favored 'General case' 0 CA--C 1.536 0.413 0 O-C-N 121.338 -0.851 . . . . 0.02 112.151 175.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 6' ' ' GLY . . . . . . . . . . . . . . . 124.84 44.22 0.28 Allowed Glycine 0 CA--C 1.523 0.543 0 CA-C-O 119.136 -0.813 . . . . 0.01 112.741 170.621 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 7' ' ' GLY . . . . . . . . . . . . . . . -26.5 90.44 0.01 OUTLIER Glycine 0 CA--C 1.532 1.152 0 C-N-CA 127.243 2.354 . . . . 0.01 116.144 -178.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 8' ' ' GLY . . . . . . . . . . . . . . . 60.73 16.11 44.24 Favored Glycine 0 CA--C 1.531 1.079 0 CA-C-O 118.112 -1.382 . . . . 0.0 115.034 176.428 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' ASP . . . . . . . . . . . . . 34.8 t0 69.17 -39.91 0.44 Allowed 'General case' 0 N--CA 1.479 1.005 0 CA-C-N 120.22 2.01 . . . . 0.06 113.703 -174.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' GLY . . . . . . . . . . . . . . . -85.21 4.6 85.31 Favored Glycine 0 CA--C 1.527 0.807 0 C-N-CA 125.18 1.372 . . . . 0.03 113.793 178.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' SER . . . . . . . . . . . . . 50.7 m -136.02 108.44 7.37 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 119.291 1.546 . . . . 0.01 110.014 163.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' LEU . . . . . . . . . . . . . 23.3 tp -70.45 74.61 0.54 Allowed 'General case' 0 CA--C 1.533 0.325 0 O-C-N 121.452 -0.78 . . . . 0.03 111.524 -177.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' ALA . . . . . . . . . . . . . . . -154.57 173.02 16.9 Favored 'General case' 0 C--N 1.327 -0.394 0 C-N-CA 122.981 0.512 . . . . 0.02 110.536 -165.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' PHE . . . . . . . . . . . . . 40.7 m-85 -82.78 164.92 20.3 Favored 'General case' 0 C--N 1.33 -0.246 0 O-C-N 121.935 -0.478 . . . . 0.02 111.426 166.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' LEU . . . . . . . . . . . . . 34.8 mt -133.91 118.66 14.39 Favored Pre-proline 0 CA--C 1.538 0.498 0 C-N-CA 123.487 0.715 . . . . 0.02 109.513 152.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -72.41 161.34 92.86 Favored 'Cis proline' 0 CA--C 1.533 0.443 0 CA-C-N 119.919 1.007 . . . . 0.02 112.972 -3.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' GLY . . . . . . . . . . . . . . . -100.22 -12.46 39.15 Favored Glycine 0 CA--C 1.531 1.033 0 C-N-CA 123.87 0.747 . . . . 0.03 112.244 172.734 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -142.67 126.06 16.65 Favored 'General case' 0 C--N 1.331 -0.223 0 C-N-CA 124.558 1.143 . . . . 0.03 109.769 168.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 2.6 p90 -151.86 175.02 12.89 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 121.0 -1.063 . . . . 0.02 109.976 174.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' SER . . . . . . . . . . . . . 8.1 m -131.32 157.84 42.28 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 118.369 0.531 . . . . 0.02 109.897 179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' VAL . . . . . . . . . . . . . 17.1 m -142.03 169.78 13.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 110.155 -0.313 . . . . 0.02 110.155 -177.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' ALA . . . . . . . . . . . . . . . -99.22 162.32 13.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.759 0.79 . . . . 0.02 111.186 167.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' SER . . . . . . . . . . . . . 4.9 t -70.88 132.67 45.6 Favored 'General case' 0 C--N 1.327 -0.392 0 O-C-N 120.874 -1.141 . . . . 0.02 110.448 -179.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' GLY . . . . . . . . . . . . . . . 92.79 -0.21 69.76 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 124.431 1.015 . . . . 0.02 113.079 -179.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLU . . . . . . . . . . . . . 77.2 mm-40 -83.02 170.31 15.01 Favored 'General case' 0 CA--C 1.534 0.337 0 O-C-N 121.787 -0.831 . . . . 0.02 110.449 174.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -118.5 127.25 53.46 Favored 'General case' 0 C--O 1.233 0.185 0 O-C-N 121.715 -0.616 . . . . 0.02 111.616 -175.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ILE . . . . . . . . . . . . . 4.1 mp -93.08 134.23 31.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 N-CA-C 108.637 -0.875 . . . . 0.02 108.637 169.508 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' VAL . . . . . . . . . . . . . 95.2 t -110.31 113.45 44.25 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.286 0 N-CA-C 109.082 -0.71 . . . . 0.02 109.082 174.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -94.29 120.49 34.6 Favored 'General case' 0 C--N 1.322 -0.611 0 O-C-N 120.983 -1.073 . . . . 0.02 109.414 176.584 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' LYS . . . . . . . . . . . . . 41.3 pttt -130.51 153.67 48.59 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 121.343 -0.848 . . . . 0.03 111.955 -177.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ASN . . . . . . . . . . . . . 4.9 m-20 -75.89 161.4 29.0 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 123.079 0.552 . . . . 0.03 111.242 -177.968 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -138.34 -43.25 0.5 Allowed 'General case' 0 N--CA 1.468 0.442 0 O-C-N 120.849 -1.157 . . . . 0.02 113.501 165.057 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' ALA . . . . . . . . . . . . . . . -157.36 172.51 18.46 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 118.275 -0.869 . . . . 0.03 109.14 -173.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' GLY . . . . . . . . . . . . . . . 67.61 29.56 74.06 Favored Glycine 0 CA--C 1.53 1.026 0 CA-C-N 119.586 1.084 . . . . 0.09 115.27 165.216 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' PHE . . . . . . . . . . . . . 12.1 m-85 -59.87 160.98 13.14 Favored Pre-proline 0 C--O 1.236 0.381 0 N-CA-C 114.119 1.155 . . . . 0.09 114.119 -167.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -88.18 171.02 34.0 Favored 'Cis proline' 0 CA--C 1.53 0.322 0 C-N-CA 129.175 0.906 . . . . 0.06 113.083 -3.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' HIS . . . . . . . . . . . . . 94.0 m-70 -144.01 177.59 8.46 Favored 'General case' 0 CA--C 1.533 0.308 0 C-N-CA 123.025 0.53 . . . . 0.05 112.203 175.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' ASN . . . . . . . . . . . . . 41.5 p-10 -159.85 -178.57 7.14 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.181 1.392 . . . . 0.1 107.356 179.359 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 1.6 t -129.5 133.18 65.7 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.499 0 CA-C-O 121.73 0.776 . . . . 0.07 111.439 165.192 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 47.6 t -132.4 120.0 41.23 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 114.421 -1.263 . . . . 0.11 110.176 179.66 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 41' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -77.72 135.4 38.03 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.319 -0.863 . . . . 0.12 110.529 173.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 42' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -79.29 107.84 12.35 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.215 -0.928 . . . . 0.34 113.018 -170.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 43' ' ' GLU . . . . . . . . . . . . . 8.8 pt-20 -58.47 -10.68 2.29 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 115.573 1.694 . . . . 0.33 115.573 -167.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 44' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -100.39 -10.75 20.87 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.937 0.895 . . . . 0.34 112.841 179.547 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 45' ' ' GLU . . . . . . . . . . . . . 28.1 mt-10 -128.5 -13.17 4.89 Favored 'General case' 0 N--CA 1.469 0.524 0 N-CA-C 114.321 1.23 . . . . 0.55 114.321 -173.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 46' ' ' ILE . . . . . . . . . . . . . 10.7 pt -56.05 163.45 2.26 Favored Pre-proline 0 N--CA 1.475 0.788 0 CA-C-N 118.926 0.784 . . . . 0.07 111.606 167.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 47' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -71.04 165.18 33.22 Favored 'Trans proline' 0 N--CA 1.452 -0.914 0 C-N-CA 121.066 1.178 . . . . 0.05 110.963 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 48' ' ' SER . . . . . . . . . . . . . 28.3 m -75.14 -28.6 60.23 Favored 'General case' 0 C--N 1.325 -0.475 0 O-C-N 121.35 -0.844 . . . . 0.04 112.724 -171.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 49' ' ' GLY . . . . . . . . . . . . . . . -78.73 18.09 6.22 Favored Glycine 0 CA--C 1.53 1.008 0 N-CA-C 116.092 1.197 . . . . 0.04 116.092 -173.598 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 50' ' ' VAL . . . . . . . . . . . . . 2.8 p -145.8 169.17 6.8 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.333 0 CA-C-N 119.012 1.406 . . . . 0.05 109.99 -178.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 51' ' ' ASP . . . . . . . . . . . . . 58.4 t0 -118.43 128.61 54.78 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 125.045 1.338 . . . . 0.1 108.838 166.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 52' ' ' ALA . . . . . . . . . . . . . . . -53.66 -26.97 24.83 Favored 'General case' 0 CA--C 1.53 0.21 0 O-C-N 121.433 -0.792 . . . . 0.09 111.66 177.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.76 -8.23 10.0 Favored 'General case' 0 CA--C 1.541 0.603 0 O-C-N 120.551 -1.343 . . . . 0.07 114.404 178.676 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 54' ' ' LYS . . . . . . . . . . . . . 13.0 mmmm -98.67 -7.41 27.92 Favored 'General case' 0 N--CA 1.468 0.43 0 O-C-N 121.251 -0.905 . . . . 0.06 113.076 171.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 55' ' ' ILE . . . . . . . . . . . . . 40.3 pt -130.95 -25.17 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 113.698 0.999 . . . . 0.06 113.698 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 56' ' ' SER . . . . . . . . . . . . . 49.1 m -71.58 160.69 32.23 Favored 'General case' 0 N--CA 1.465 0.308 0 O-C-N 120.866 -1.146 . . . . 0.07 111.334 165.055 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 57' ' ' MET . . . . . . . . . . . . . 85.8 mtp -73.54 168.12 19.92 Favored 'General case' 0 CA--C 1.535 0.383 0 O-C-N 121.658 -0.651 . . . . 0.08 110.649 166.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 58' ' ' SER . . . . . . . . . . . . . 1.5 m -70.71 155.25 41.0 Favored 'General case' 0 N--CA 1.466 0.355 0 O-C-N 121.659 -0.65 . . . . 0.1 111.503 172.093 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 59' ' ' GLU . . . . . . . . . . . . . 69.6 tt0 -61.14 -27.97 68.77 Favored 'General case' 0 CA--C 1.537 0.475 0 N-CA-C 114.498 1.295 . . . . 0.28 114.498 -167.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 60' ' ' GLU . . . . . . . . . . . . . 26.5 mt-10 -111.53 15.48 21.15 Favored 'General case' 0 N--CA 1.466 0.339 0 C-N-CA 124.206 1.002 . . . . 0.24 112.4 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 61' ' ' ASP . . . . . . . . . . . . . 40.7 t0 -101.84 113.91 27.52 Favored 'General case' 0 CA--C 1.536 0.405 0 O-C-N 121.48 -0.762 . . . . 0.06 111.5 172.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 62' ' ' LEU . . . . . . . . . . . . . 4.0 mp -137.83 150.15 46.94 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.328 -0.857 . . . . 0.05 111.39 -178.434 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 63' ' ' LEU . . . . . . . . . . . . . 44.4 mt -82.72 110.32 17.66 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 127.207 2.203 . . . . 0.03 109.942 178.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 64' ' ' ASN . . . . . . . . . . . . . 6.5 p30 -112.95 -16.29 12.71 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 114.861 1.43 . . . . 0.02 114.861 -166.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 65' ' ' ALA . . . . . . . . . . . . . . . -106.57 165.97 12.0 Favored Pre-proline 0 CA--C 1.538 0.485 0 CA-C-N 118.595 0.634 . . . . 0.01 110.659 171.831 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -48.71 -54.17 5.79 Favored 'Trans proline' 0 N--CA 1.456 -0.682 0 C-N-CA 123.901 3.067 . . . . 0.01 114.652 179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 67' ' ' GLY . . . . . . . . . . . . . . . -88.59 2.63 84.81 Favored Glycine 0 CA--C 1.526 0.725 0 O-C-N 120.92 -1.112 . . . . 0.01 114.893 -166.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 68' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -70.19 155.76 40.18 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-N 119.178 1.489 . . . . 0.02 112.961 -175.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 69' ' ' THR . . . . . . . . . . . . . 30.0 p -140.48 164.0 31.3 Favored 'General case' 0 N--CA 1.468 0.431 0 CA-C-O 122.235 1.017 . . . . 0.02 113.42 -174.885 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' TYR . . . . . . . . . . . . . 27.6 t80 -137.09 151.54 49.0 Favored 'General case' 0 C--N 1.329 -0.296 0 N-CA-C 106.916 -1.512 . . . . 0.03 106.916 167.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' LYS . . . . . . . . . . . . . 43.4 mtmt -141.33 149.08 40.72 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 119.704 1.138 . . . . 0.03 111.446 -173.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' VAL . . . . . . . . . . . . . 7.4 p -152.12 128.83 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 N-CA-C 112.512 0.56 . . . . 0.02 112.512 176.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' THR . . . . . . . . . . . . . 61.8 m -76.79 128.02 33.83 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 108.131 -1.063 . . . . 0.02 108.131 162.516 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' LEU . . . . . . . . . . . . . 5.8 tp -118.2 154.67 31.82 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 119.153 0.888 . . . . 0.02 111.594 -173.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' THR . . . . . . . . . . . . . 39.1 p -152.49 176.91 11.18 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 108.169 -1.048 . . . . 0.03 108.169 -176.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' GLU . . . . . . . . . . . . . 75.9 mm-40 78.28 115.53 0.06 Allowed 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 128.082 2.553 . . . . 0.03 111.901 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' LYS . . . . . . . . . . . . . 34.5 mttt -70.12 101.25 1.8 Allowed 'General case' 0 CA--C 1.52 -0.174 0 C-N-CA 123.779 0.831 . . . . 0.03 112.313 -175.03 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' GLY . . . . . . . . . . . . . . . -172.15 177.38 44.86 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 111.881 -0.488 . . . . 0.03 111.881 173.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -67.75 143.75 55.73 Favored 'General case' 0 C--N 1.332 -0.154 0 C-N-CA 124.145 0.978 . . . . 0.05 112.556 173.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' TYR . . . . . 0.65 ' CB ' HG13 ' B' ' 96' ' ' VAL 0.338 26.5 m-85 -135.04 82.05 1.93 Allowed 'General case' 0 CA--C 1.535 0.373 0 CA-C-O 124.498 2.094 . . . . 0.05 111.332 -175.79 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' LYS . . . . . . . . . . . . . 88.1 mttt -71.01 115.4 10.09 Favored 'General case' 0 C--N 1.33 -0.261 0 O-C-N 119.725 -1.86 . . . . 0.09 110.804 162.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' PHE . . . . . 0.487 ' HE1' ' H ' ' B' ' 96' ' ' VAL . 0.4 OUTLIER -126.43 139.45 53.24 Favored 'General case' 0 CA--C 1.507 -0.673 0 CA-C-O 122.748 1.261 . . . . 0.07 108.078 163.343 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' TYR . . . . . 0.411 ' HB3' HG13 ' B' ' 93' ' ' VAL . 0.1 OUTLIER -133.23 177.12 7.92 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 114.286 -1.325 . . . . 0.15 107.601 -173.698 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' CYS . . . . . . . . . . . . . 28.0 t -110.68 108.96 19.03 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.555 -0.535 . . . . 0.09 109.555 178.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' SER . . . . . . . . . . . . . 1.8 p -56.16 -32.07 11.86 Favored Pre-proline 0 CA--C 1.535 0.403 0 N-CA-C 116.478 2.029 . . . . 0.09 116.478 -162.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_exo -63.43 -28.21 71.02 Favored 'Trans proline' 0 CA--C 1.534 0.501 0 CA-C-N 122.113 1.79 . . . . 0.15 113.669 171.398 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' HIS . . . . . . . . . . . . . 28.4 m170 -122.84 -4.27 8.62 Favored 'General case' 0 CA--C 1.539 0.531 0 N-CA-C 114.221 1.193 . . . . 0.05 114.221 -166.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -57.14 -37.82 72.59 Favored 'General case' 0 N--CA 1.467 0.419 0 O-C-N 121.092 -1.005 . . . . 0.27 112.079 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' GLY . . . . . . . . . . . . . . . -75.29 -32.38 55.69 Favored Glycine 0 CA--C 1.528 0.877 0 O-C-N 120.487 -1.383 . . . . 0.0 111.31 176.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' ALA . . . . . . . . . . . . . . . -70.19 -9.24 55.12 Favored 'General case' 0 CA--C 1.538 0.488 0 O-C-N 121.621 -0.929 . . . . 0.05 112.322 172.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' GLY . . . . . . . . . . . . . . . 121.91 -9.35 9.76 Favored Glycine 0 CA--C 1.527 0.805 0 C-N-CA 123.726 0.679 . . . . 0.04 113.767 170.56 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' MET . . . . . . . . . . . . . 16.6 ttt -72.07 86.38 1.04 Allowed 'General case' 0 CA--C 1.534 0.342 0 CA-C-N 118.439 1.12 . . . . 0.05 112.797 -177.285 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' VAL . . . . . 0.411 HG13 ' HB3' ' B' ' 83' ' ' TYR . 4.2 t -128.72 142.17 44.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 C-N-CA 124.244 1.018 . . . . 0.05 108.865 179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -126.23 151.75 18.03 Favored Glycine 0 N--CA 1.451 -0.361 0 N-CA-C 109.497 -1.441 . . . . 0.04 109.497 173.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' LYS . . . . . . . . . . . . . 13.0 ttpp -123.92 93.32 3.89 Favored 'General case' 0 C--N 1.331 -0.231 0 C-N-CA 123.38 0.672 . . . . 0.04 110.456 177.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' VAL . . . . . 0.65 HG13 ' CB ' ' B' ' 80' ' ' TYR . 8.2 p -78.2 162.35 4.09 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 N-CA-C 107.21 -1.404 . . . . 0.03 107.21 164.65 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' THR . . . . . . . . . . . . . 18.3 m -153.93 130.89 10.96 Favored 'General case' 0 C--N 1.324 -0.511 0 O-C-N 119.742 -1.849 . . . . 0.03 107.435 173.696 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' VAL . . . . . . . . . . . . . 58.9 t -89.65 111.69 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 108.732 -0.84 . . . . 0.02 108.732 178.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 99' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.247 0.933 0 N-CA-C 114.024 1.12 . . . . 0.02 114.024 -170.384 . . . . . . . . 1 1 . 1 stop_ save_